 | | Vol. 9.05 – 10 February, 2021 |
| |
|
|
| Scientists report on the antibody and memory B cell responses in a cohort of 20 volunteers who received either the Moderna or Pfizer-BioNTech vaccines.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors quantified levels of SARS-CoV-2-reactive antibodies and human coronavirus-reactive antibodies in serum samples collected from 431 humans before the COVID-19 pandemic.
[Cell] |
|
|
|
| The role of SARS-CoV-2-specific T cell immunity, its relationship to antibodies, and pre-existing immunity against endemic coronaviruses, which had been hypothesized to be protective, were investigated in healthy donors, recovered, and active COVID-19 patients.
[Immunity] |
|
|
|
| Researchers studied the immune cell landscape, with emphasis on mucosal-associated invariant T (MAIT) cells, in cohorts totaling 208 patients with various stages of disease.
[Nature Immunology] |
|
|
|
| Investigators mapped how convalescent plasma antibodies were impacted by all mutations to the spike’s receptor-binding domain, the main target of plasma neutralizing activity.
[Cell Host & Microbe] |
|
|
|
| A muted immune response was observed in COVID-19 relative to other infections with paradoxical down-regulation of several key differentially expressed genes.
[Science Advances] |
|
|
|
| Scientists evaluated the antiviral efficacy of enzalutamide in prostate cancer cells, lung cancer cells, human lung organoids and Ad-ACE2-transduced mice.
[Nature Communications] |
|
|
|
| The authors developed a nucleoside-modified mRNA vaccine in lipid-encapsulated form that encoded the SARS-CoV-2 RBD, termed as mRNA-RBD. A single immunization of mRNA-RBD elicited both robust neutralizing antibody and cellular responses, and conferred a near-complete protection against wild SARS-CoV-2 infection in the lungs of hACE2 transgenic mice.
[Nature Communications] |
|
|
|
| Using primary epithelial organoids from human colon, researchers explored how the central antiviral mediator IFN‐γ, which is elevated in COVID‐19, affected epithelial cell differentiation, ACE2 expression, and susceptibility to infection with SARS‐CoV‐2.
[EMBO Molecular Medicine] |
|
|
|
| Investigators selected plasma from a cohort of COVID-19 convalescent patients and selectively depleted immunoglobulin A, M or G before testing the remaining neutralizing capacity of the depleted plasma.
[Cell Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists report that the CARD8 inflammasome sensed HIV-1 protease activity. HIV-1 could evade CARD8 sensing because its protease remained inactive in infected cells prior to viral budding.
[Science] |
|
|
|
| Using a multi-kingdom antibody profiling approach, researchers explored the human antibody repertoires against gut commensal fungi.
[Cell] |
|
|
|
| Investigators demonstrated a critical role for the immune system in supporting fecal microbiota transplantation using a murine C. difficile infection system.
[Nature Communications] |
|
|
|
| Researchers used single-cell RNA sequencing to examine the diversity of both antigen-specific and total B cells in healthy subjects and malaria-exposed individuals.
[Cell Reports] |
|
|
|
|
| The authors summarize evidence for the host, bacterial and environmental factors that influence IgA–microbiota interactions.
[Nature Reviews Immunology] |
|
|
|
| Scientists describe the current arsenal of antifungal agents and the treatment strategies employed to manage cryptococcal disease.
[Nature Reviews Microbiology] |
|
|
|
| A hyperinflammatory ‘cytokine storm’ state termed macrophage activation syndrome, culminating from a complex interplay of genetics, immunodeficiency, infectious triggers and dominant innate immune effector responses, can develop across disparate entities including systemic juvenile idiopathic arthritis
[Nature Reviews Rheumatology] |
|
|
|
|
| Turn Therapeutics, Inc. announced enrollment of the first subjects in its COVID-19 treatment and prevention clinical trial. Turn’s flagship product, Hexagen, will be administered intranasally and studied as a method for reducing viral load, as well as uptake, at the critical infection points that line the nasal passage.
[Turn Therapeutics, Inc. (BusinessWire, Inc)] |
|
|
|
| COVAXX announced positive interim Phase I data from its open-label COVID-19 clinical trial conducted in Taiwan. This study, which evaluated the safety, tolerability, and immunogenicity of UB-612, showed that the vaccine was generally well-tolerated and elicited robust antibody responses comparable to those seen in human convalescent sera.
[COVAXX (BusinessWire, Inc)] |
|
|
|
|
| February 22 – 26, 2021
Virtual |
|
|
|
|
|
| | Helmholtz Centre for Infection Research – Würzburg, Germany |
|
|
|
| | NCCR AntiResist – Basel, Switzerland |
|
|
|
| | University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| | UT Health Science Center at Tyler – Tyler, Texas, United States |
|
|
|
| | Stanford School of Medicine – Stanford, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
